Catherine Kimber
@thrinaline.bsky.social
Proud to work for the NHS. Trying to adhere to sustainable travel in a small and imperfect way. Loves books, gardening, singing and Jet Lag the Game. Any views expressed are my own and not representative of my employer.
Reposted by Catherine Kimber
🟠Today we are celebrating #WorldPatientSafetyDay and also five years of the Transfusion Evidence Round-Up, which we produce in partnership with @isbt.bsky.social.
🔗Read more on the SRI website (link in replies)
🔗Read more on the SRI website (link in replies)
September 17, 2026 at 12:17 PM
🟠Today we are celebrating #WorldPatientSafetyDay and also five years of the Transfusion Evidence Round-Up, which we produce in partnership with @isbt.bsky.social.
🔗Read more on the SRI website (link in replies)
🔗Read more on the SRI website (link in replies)
Reposted by Catherine Kimber
🔗 #StemCellEvidence link to:
Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A #SystematicReview of Efficacy and Toxicity
by Shafqat et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A #SystematicReview of Efficacy and Toxicity
by Shafqat et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A Systematic Review of Efficacy and Toxicity
The standard 100 mg/kg dose of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis after matched allogeneic stem cell transplantation (ASCT) is associated with imp...
www.stemcellevidence.com
September 1, 2026 at 7:41 AM
🔗 #StemCellEvidence link to:
Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A #SystematicReview of Efficacy and Toxicity
by Shafqat et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A #SystematicReview of Efficacy and Toxicity
by Shafqat et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Reposted by Catherine Kimber
🔗 #StemCellEvidence link to:
Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes
by Popat et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes
by Popat et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes
BACKGROUND: A myeloablative busulfan (Bu) and fludarabine (Flu) regimen that includes fractionating Bu and extending its delivery time results in low toxicity, permitting its use in stem cell transpla...
www.stemcellevidence.com
September 1, 2026 at 7:43 AM
🔗 #StemCellEvidence link to:
Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes
by Popat et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes
by Popat et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Reposted by Catherine Kimber
🟣 New from the #StemCellEvidence alert:
📑 Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes
by Popat et al.
🔗 Link in the comments
#MedSky
📑 Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes
by Popat et al.
🔗 Link in the comments
#MedSky
September 1, 2026 at 7:42 AM
🟣 New from the #StemCellEvidence alert:
📑 Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes
by Popat et al.
🔗 Link in the comments
#MedSky
📑 Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes
by Popat et al.
🔗 Link in the comments
#MedSky
Reposted by Catherine Kimber
📆September is #BloodCancerAwarenessMonth. To honour this, episode 4 of our Talking Transfusion Podcast explores recent relevant findings, clinical challenges, and how transfusion supports those living with leukemia, lymphoma, myeloma, and related conditions. Links to the podcast here: bit.ly/45VghOf
Talking Transfusion Podcast
A collaborative podcast featuring the latest systematic reviews and trials
bit.ly
September 1, 2026 at 11:23 AM
📆September is #BloodCancerAwarenessMonth. To honour this, episode 4 of our Talking Transfusion Podcast explores recent relevant findings, clinical challenges, and how transfusion supports those living with leukemia, lymphoma, myeloma, and related conditions. Links to the podcast here: bit.ly/45VghOf
Reposted by Catherine Kimber
#StemCellEvidence link to:
Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation by Ginosyan et al.
www.stemcellevidence.com/alerts/artic...
Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation by Ginosyan et al.
www.stemcellevidence.com/alerts/artic...
https://www.stemcellevidence.com/alerts/articles/42276849
www.stemcellevidence.com
August 24, 2026 at 10:00 AM
#StemCellEvidence link to:
Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation by Ginosyan et al.
www.stemcellevidence.com/alerts/artic...
Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation by Ginosyan et al.
www.stemcellevidence.com/alerts/artic...
Reposted by Catherine Kimber
#StemCellEvidence link to:
The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy
by Greco et al.
www.stemcellevidence.com/alerts/artic...
The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy
by Greco et al.
www.stemcellevidence.com/alerts/artic...
https://www.stemcellevidence.com/alerts/articles/42203900
www.stemcellevidence.com
August 24, 2026 at 10:00 AM
#StemCellEvidence link to:
The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy
by Greco et al.
www.stemcellevidence.com/alerts/artic...
The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy
by Greco et al.
www.stemcellevidence.com/alerts/artic...
Reposted by Catherine Kimber
✅New from the #TransfusionEvidence Alert:
🩸Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in #blooddonors
by Geneen et al.
🔗Link in the comments
#MedSky #blooddonation @thrinaline.bsky.social @willmcclune.bsky.social
🩸Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in #blooddonors
by Geneen et al.
🔗Link in the comments
#MedSky #blooddonation @thrinaline.bsky.social @willmcclune.bsky.social
July 27, 2026 at 7:43 AM
✅New from the #TransfusionEvidence Alert:
🩸Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in #blooddonors
by Geneen et al.
🔗Link in the comments
#MedSky #blooddonation @thrinaline.bsky.social @willmcclune.bsky.social
🩸Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in #blooddonors
by Geneen et al.
🔗Link in the comments
#MedSky #blooddonation @thrinaline.bsky.social @willmcclune.bsky.social
Reposted by Catherine Kimber
🔗 #StemCellEvidence link to:
The impact of the cryopreservation period on the CD34+ cell viability of cryopreserved cord blood units
by Lee et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
The impact of the cryopreservation period on the CD34+ cell viability of cryopreserved cord blood units
by Lee et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
The impact of the cryopreservation period on the CD34+ cell viability of cryopreserved cord blood units
BACKGROUND AND OBJECTIVES: Cord blood (CB) is an important source for haematopoietic stem cell transplantation because of its long-term cryopreservation. However, concerns remain regarding the potenti...
www.stemcellevidence.com
July 8, 2026 at 8:45 AM
🔗 #StemCellEvidence link to:
The impact of the cryopreservation period on the CD34+ cell viability of cryopreserved cord blood units
by Lee et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
The impact of the cryopreservation period on the CD34+ cell viability of cryopreserved cord blood units
by Lee et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Reposted by Catherine Kimber
🔴New from the #TransfusionEvidence Alert:
Clinical Outcomes of Intravenous Albumin Administration After Acute Variceal Hemorrhage in Patients with Cirrhosis: An Open-Label, Randomized Controlled Trial
by Biswas et al.
🔗Link in the comments.
#MedSky
Clinical Outcomes of Intravenous Albumin Administration After Acute Variceal Hemorrhage in Patients with Cirrhosis: An Open-Label, Randomized Controlled Trial
by Biswas et al.
🔗Link in the comments.
#MedSky
June 29, 2026 at 2:28 PM
🔴New from the #TransfusionEvidence Alert:
Clinical Outcomes of Intravenous Albumin Administration After Acute Variceal Hemorrhage in Patients with Cirrhosis: An Open-Label, Randomized Controlled Trial
by Biswas et al.
🔗Link in the comments.
#MedSky
Clinical Outcomes of Intravenous Albumin Administration After Acute Variceal Hemorrhage in Patients with Cirrhosis: An Open-Label, Randomized Controlled Trial
by Biswas et al.
🔗Link in the comments.
#MedSky
Reposted by Catherine Kimber
🆕The latest #StemCellEvidence alert is out!
🟣See the top 10 articles in the #StemCell Evidence Alert - June 2026. Each one has an easy-to-read PICO summary.
🔗Link in the comments
#MedSky
🟣See the top 10 articles in the #StemCell Evidence Alert - June 2026. Each one has an easy-to-read PICO summary.
🔗Link in the comments
#MedSky
June 29, 2026 at 2:02 PM
🆕The latest #StemCellEvidence alert is out!
🟣See the top 10 articles in the #StemCell Evidence Alert - June 2026. Each one has an easy-to-read PICO summary.
🔗Link in the comments
#MedSky
🟣See the top 10 articles in the #StemCell Evidence Alert - June 2026. Each one has an easy-to-read PICO summary.
🔗Link in the comments
#MedSky
Reposted by Catherine Kimber
Reposted by Catherine Kimber
It is so exciting to be in the #ISBTCongress 2026, in Kuala Lumpur, learning, connecting, and presenting our research posters!
@thrinaline.bsky.social @isbt.bsky.social
#ISBTKualaLumpur
#TransfusionMedicine
@thrinaline.bsky.social @isbt.bsky.social
#ISBTKualaLumpur
#TransfusionMedicine
June 23, 2026 at 2:00 PM
It is so exciting to be in the #ISBTCongress 2026, in Kuala Lumpur, learning, connecting, and presenting our research posters!
@thrinaline.bsky.social @isbt.bsky.social
#ISBTKualaLumpur
#TransfusionMedicine
@thrinaline.bsky.social @isbt.bsky.social
#ISBTKualaLumpur
#TransfusionMedicine
Reposted by Catherine Kimber
What a privilege to participate in the #ISBTCongress 2026, advancing knowledge and collaborating with colleagues through poster presentations and workshops!
@thrinaline.bsky.social @ericawood.bsky.social
#ISBTKualaLumpur
#TransfusionMedicine
#ISBT #Transfusion
@thrinaline.bsky.social @ericawood.bsky.social
#ISBTKualaLumpur
#TransfusionMedicine
#ISBT #Transfusion
June 23, 2026 at 3:22 PM
What a privilege to participate in the #ISBTCongress 2026, advancing knowledge and collaborating with colleagues through poster presentations and workshops!
@thrinaline.bsky.social @ericawood.bsky.social
#ISBTKualaLumpur
#TransfusionMedicine
#ISBT #Transfusion
@thrinaline.bsky.social @ericawood.bsky.social
#ISBTKualaLumpur
#TransfusionMedicine
#ISBT #Transfusion
Reposted by Catherine Kimber
✅You can also find more high-quality research about #SickleCell disease in the @transfusionlib.bsky.social and @stemcellevidence.bsky.social
June 19, 2026 at 9:28 AM
✅You can also find more high-quality research about #SickleCell disease in the @transfusionlib.bsky.social and @stemcellevidence.bsky.social
Reposted by Catherine Kimber
It's #NationalBloodWeek. This year's #NHSBT theme is 'we are the giving types because of you', recognising all areas of the organisation working to improve lives. Our role is in evidence synthesis and provision. You can access the latest publications on blood components use on our TEL bit.ly/4uhJVqt
June 10, 2026 at 11:23 AM
It's #NationalBloodWeek. This year's #NHSBT theme is 'we are the giving types because of you', recognising all areas of the organisation working to improve lives. Our role is in evidence synthesis and provision. You can access the latest publications on blood components use on our TEL bit.ly/4uhJVqt
Reposted by Catherine Kimber
🔗 #StemCellEvidence link to:
Letermovir improves the outcome of allogenic stem cell transplantation with anti-thymocyte globulin against acute leukemia and myelodysplastic syndromes
by Negishi et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Letermovir improves the outcome of allogenic stem cell transplantation with anti-thymocyte globulin against acute leukemia and myelodysplastic syndromes
by Negishi et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Letermovir improves the outcome of allogenic stem cell transplantation with anti-thymocyte globulin against acute leukemia and myelodysplastic syndromes
Graft versus host disease (GVHD) is a serious side effect of allogenic stem cell transplantation (allo-SCT). Anti-thymocyte globulin (ATG) reduces GVHD but raises the risk of infections following allo...
www.stemcellevidence.com
June 8, 2026 at 10:47 AM
🔗 #StemCellEvidence link to:
Letermovir improves the outcome of allogenic stem cell transplantation with anti-thymocyte globulin against acute leukemia and myelodysplastic syndromes
by Negishi et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Letermovir improves the outcome of allogenic stem cell transplantation with anti-thymocyte globulin against acute leukemia and myelodysplastic syndromes
by Negishi et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Newly minted ladybird?
June 5, 2026 at 4:49 PM
Newly minted ladybird?
Reposted by Catherine Kimber
From the #StemCellEvidence alert:
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
by Hansen et al.
🔗 Link in the comments
#MedSky
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
by Hansen et al.
🔗 Link in the comments
#MedSky
June 4, 2026 at 10:56 AM
From the #StemCellEvidence alert:
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
by Hansen et al.
🔗 Link in the comments
#MedSky
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
by Hansen et al.
🔗 Link in the comments
#MedSky
Reposted by Catherine Kimber
New from the #TransfusionEvidence Alert:
Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate-to-severe postpartum anaemia in Nigerian women (IVON-PP): an open-label, randomised controlled trial
by Afolabi et al.
🔗 Link in the comments
#MedSky
Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate-to-severe postpartum anaemia in Nigerian women (IVON-PP): an open-label, randomised controlled trial
by Afolabi et al.
🔗 Link in the comments
#MedSky
May 22, 2026 at 6:18 AM
New from the #TransfusionEvidence Alert:
Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate-to-severe postpartum anaemia in Nigerian women (IVON-PP): an open-label, randomised controlled trial
by Afolabi et al.
🔗 Link in the comments
#MedSky
Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate-to-severe postpartum anaemia in Nigerian women (IVON-PP): an open-label, randomised controlled trial
by Afolabi et al.
🔗 Link in the comments
#MedSky
Reposted by Catherine Kimber
From the #StemCellEvidence Alert:
Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide
by Smallbone et al.
🔗 Link in the comments
#MedSky
Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide
by Smallbone et al.
🔗 Link in the comments
#MedSky
May 15, 2026 at 9:57 AM
From the #StemCellEvidence Alert:
Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide
by Smallbone et al.
🔗 Link in the comments
#MedSky
Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide
by Smallbone et al.
🔗 Link in the comments
#MedSky
Reposted by Catherine Kimber
From the #StemCellEvidence Alert:
Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib
by Massoud et al.
Link in the comments
#MedSky
Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib
by Massoud et al.
Link in the comments
#MedSky
May 13, 2026 at 6:46 AM
From the #StemCellEvidence Alert:
Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib
by Massoud et al.
Link in the comments
#MedSky
Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib
by Massoud et al.
Link in the comments
#MedSky
Reposted by Catherine Kimber
New from the #StemCellEvidence Alert:
Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study
by Malagola et al.
🔗 Link in the comments
#MedSky
Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study
by Malagola et al.
🔗 Link in the comments
#MedSky
May 12, 2026 at 8:49 AM
New from the #StemCellEvidence Alert:
Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study
by Malagola et al.
🔗 Link in the comments
#MedSky
Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study
by Malagola et al.
🔗 Link in the comments
#MedSky
Reposted by Catherine Kimber
Good points in this piece from Chris Rapley:
"Not once in the history of human spaceflight has an astronaut been known to tamper with their life support system...
Sabotage is unthinkable – socially intolerable...
We are doing to our planetary life support what no astronaut has done to theirs. "
"Not once in the history of human spaceflight has an astronaut been known to tamper with their life support system...
Sabotage is unthinkable – socially intolerable...
We are doing to our planetary life support what no astronaut has done to theirs. "
Why we need to treat Earth like a spaceship
Climate science is the anti-myth. Researchers have long noted that the human brain struggles with psychologically distant threats.
theconversation.com
May 10, 2026 at 9:55 AM
Good points in this piece from Chris Rapley:
"Not once in the history of human spaceflight has an astronaut been known to tamper with their life support system...
Sabotage is unthinkable – socially intolerable...
We are doing to our planetary life support what no astronaut has done to theirs. "
"Not once in the history of human spaceflight has an astronaut been known to tamper with their life support system...
Sabotage is unthinkable – socially intolerable...
We are doing to our planetary life support what no astronaut has done to theirs. "
Reposted by Catherine Kimber
Today is #InternationalThalassaemiaDay. In honour of this, the May Transfusion Evidence Round-Up and its accompanying podcast cover the topic of #thalassaemia. You can access the round-up articles here bit.ly/4cZONeJ, and the podcast here bit.ly/431jxG5
Transfusion Evidence Library
The Transfusion Evidence Library is a database of systematic reviews (since 1980) and randomised controlled trials (since 1950) relevant to transfusion medicine.
It is fully searchable, updated monthl...
bit.ly
May 8, 2026 at 12:12 PM
Today is #InternationalThalassaemiaDay. In honour of this, the May Transfusion Evidence Round-Up and its accompanying podcast cover the topic of #thalassaemia. You can access the round-up articles here bit.ly/4cZONeJ, and the podcast here bit.ly/431jxG5